Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Apr;13(4):363-9.
doi: 10.3779/j.issn.1009-3419.2010.04.18.

[A review of epidermal growth factor receptor/HER2 inhibitors in the treatment of patients with non-small-cell lung cancer]

[Article in Chinese]
Ramaswamy Govindan  1
Affiliations
Review

[A review of epidermal growth factor receptor/HER2 inhibitors in the treatment of patients with non-small-cell lung cancer]

[Article in Chinese]
Ramaswamy Govindan. Zhongguo Fei Ai Za Zhi. 2010 Apr.

Abstract

晚期非小细胞肺癌（non-small cell lung cancer, NSCLC）仍然是主要的全球健康问题。尽管可逆性表皮生长因子受体（epidermal growth factor receptor, EGFR）酪氨酸激酶抑制剂厄洛替尼可改善复发与再发NSCLC患者的生存期，但也存在明显的局限性，包括仅对少数患者亚群具有临床疗效、生存率较低及产生耐药性。EGFR和HER2的非可逆性抑制剂是临床开发的新型药物，有可能预防并克服第一代EGFR抑制剂的获得性耐药。

PubMed Disclaimer

Figures

A：EGFR(ErbB1)、HER2(ErbB1)、HER3(ErbB3)、HER4(ErbB4)基因编码4个ErbB受体。有11个生长因子可结合于这些受体，包括：EGF、转化生长因子-α、双调蛋白、纤维素、epigen、表皮调节蛋白、肝素结合EGF和4个神经调节蛋白。神经调节蛋白为HER3和HER4二聚体的配体。B：配体结合可触发受体的同源二聚化和异源二聚化。尽管EGFR抑制剂仅可阻断EGFR介导的信号传导，但抑制EGFR和HER2可阻断所有来自NSCLC相关的同源二聚体和异源二聚体的信号传导。<break/>缩写：EGFR=表皮生长因子受体。<break/>注：本图得到版权所有者©CIG Media Group, L.P.复制许可
1
ErbB信号的协同作用和所有EGFR抑制剂对比EGFR/HER2抑制剂的不同活性 Cooperative ErbB Signaling and Differential Activity of Sole EGFR Inhibition Versus EGFR/HER2 Inhibition
缩写：BSC=最佳支持治疗；CT=化疗；ECOG=东部肿瘤协作组；ORR=总有效率；OS=总生存期；PD=疾病进展；PFS=无进展生存期；PK=药代动力学；PS=体力状态；TTR=再发时间。<break/>注：本图得到版权所有者©CIG Media Group, L.P.复制许可
2
LUX Lung-1 ⅡB/Ⅲ期试验设计[34] The Phase ⅡB/Ⅲ LUX Lung-1 Trial Design[34]
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. American Cancer Society. Cancer Facts and Figures 2008. Available at: http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf. Accessed: July 13, 2009.

    1. World Health Organization. Fact Sheet No. 310. Available at: http://www.who.int/mediacentre/factsheets/fs310/en/index.html. Accessed: July 13, 2009.

    1. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–32. doi: 10.1056/NEJMoa050753. - DOI - PubMed
    1. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung cancer) Lancet. 2005;366:1527–37. doi: 10.1016/S0140-6736(05)67625-8. - DOI - PubMed
    1. Metro G, Finocchiaro G, Cappuzzo F. Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance. Ann Oncol. 2006;17(suppl 2):842–5. - PubMed

Publication types

MeSH terms